Edwards highlights new data at acc related to lifetime management of aortic stenosis

New orleans , march 6, 2023 /prnewswire/ -- edwards lifesciences (nyse: ew) today highlighted new important data examining mortality rates and cardiac damage of early-stage aortic stenosis (as) sufferers, along with data examining 10-year transcatheter aortic valve replacement (tavr) re-intervention rates using real-world medicare data.  together these studies, presented at the american college of cardiology acc.23/wcc, add valuable insights to the discussion on lifetime management of patients with as.
EW Ratings Summary
EW Quant Ranking